What does S.G. Pharma do?

S.G. Pharma is a pharmacy in Aalst. Private Limited, started on 25 January 2021, 1 establishment.

What is the address of S.G. Pharma?

The registered office of S.G. Pharma is located at Moorselbaan 345, 9300 Aalst.

Is S.G. Pharma still active?

Yes. According to the CBE (1 October 2026) S.G. Pharma is active, legal situation “Normale toestand”, started on 25 January 2021.

Is S.G. Pharma registered on Peppol?

Yes, S.G. Pharma is registered on the Peppol network with ID 0208:0762459887.

What is the enterprise number of S.G. Pharma?

The enterprise number of S.G. Pharma is BE0762459887.

When was S.G. Pharma founded?

S.G. Pharma was founded on 25 January 2021.

Who are the directors of S.G. Pharma?

According to the 2025 annual accounts, the directors of S.G. Pharma are: Santina Gorsen.

Is S.G. Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 25 January 2021; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did S.G. Pharma make in 2025?

S.G. Pharma posted a profit after taxes of € 14,601 in financial year 2025.

What is the revenue of S.G. Pharma?

As a small company, S.G. Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 29,454.

S.G. Pharma (Private Limited) - Aalst - BE0762459887

Dossier S.G. Pharma, printed on 1 October 2026 from databakkes.be/en/0762459887/s-g-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

S.G. Pharma from Aalst, company number BE0762459887, closed financial year 2025 with a result of € 14,601 after tax. For that financial year S.G. Pharma recorded a gross margin of € 29,454 and equity of € 75,422. Compared with financial year 2024, the result moved from € 15,800 to € 14,601. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.

What it is worth Healthy

€ 75,422

▼ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 14,601

▼ 8% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 43,658

▲ 51% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 16,064 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 16,701

▼ 25% vs 2024

Of which on lease € 15,180.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 15,804

▼ 30% vs 2024

€ 7,159 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 2,255

▲ 64% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 39,887 Gross margin 2022: € 39,887 First fiscal year in the series	€ 34,122 Gross margin 2023: € 34,122 ▼ 14% vs 2022 (€ 39,887) Unfavourable step	€ 31,219 Gross margin 2024: € 31,219 ▼ 9% vs 2023 (€ 34,122) Unfavourable step	€ 29,454 Gross margin 2025: € 29,454 ▼ 6% vs 2024 (€ 31,219) Unfavourable step	▼ 6%
Profit after taxes	€ 23,310 Profit after taxes 2022: € 23,310 First fiscal year in the series	€ 18,711 Profit after taxes 2023: € 18,711 ▼ 20% vs 2022 (€ 23,310) Unfavourable step	€ 15,800 Profit after taxes 2024: € 15,800 ▼ 16% vs 2023 (€ 18,711) Unfavourable step	€ 14,601 Profit after taxes 2025: € 14,601 ▼ 8% vs 2024 (€ 15,800) Unfavourable step	▼ 8%
Equity	€ 42,374 Equity 2022: € 42,374 First fiscal year in the series	€ 61,085 Equity 2023: € 61,085 ▲ 44% vs 2022 (€ 42,374) Favourable step	€ 76,885 Equity 2024: € 76,885 ▲ 26% vs 2023 (€ 61,085) Favourable step	€ 75,422 Equity 2025: € 75,422 ▼ 2% vs 2024 (€ 76,885) Unfavourable step	▼ 2%
Total debts	€ 9,978 Total debts 2022: € 9,978 First fiscal year in the series	€ 31,172 Total debts 2023: € 31,172 ▲ 212% vs 2022 (€ 9,978) Unfavourable step	€ 24,193 Total debts 2024: € 24,193 ▼ 22% vs 2023 (€ 31,172) Favourable step	€ 18,199 Total debts 2025: € 18,199 ▼ 25% vs 2024 (€ 24,193) Favourable step	▼ 25%
Cash	€ 27,491 Cash 2022: € 27,491 First fiscal year in the series	€ 14,109 Cash 2023: € 14,109 ▼ 49% vs 2022 (€ 27,491) Unfavourable step	€ 29,001 Cash 2024: € 29,001 ▲ 106% vs 2023 (€ 14,109) Favourable step	€ 43,658 Cash 2025: € 43,658 ▲ 51% vs 2024 (€ 29,001) Favourable step	▲ 51%
Retained profit	€ 39,374 Retained profit 2022: € 39,374 First fiscal year in the series	€ 58,085 Retained profit 2023: € 58,085 ▲ 48% vs 2022 (€ 39,374) Favourable step	€ 73,885 Retained profit 2024: € 73,885 ▲ 27% vs 2023 (€ 58,085) Favourable step	€ 72,422 Retained profit 2025: € 72,422 ▼ 2% vs 2024 (€ 73,885) Unfavourable step	▼ 2%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 16,064 Dividend 2025: € 16,064 Unchanged (€ 0) Unchanged
Bank debt	€ 1,431 Bank debt 2022: € 1,431 First fiscal year in the series	€ 29,456 Bank debt 2023: € 29,456 ▲ € 28,025 vs 2022 (€ 1,431) Unfavourable step	€ 22,739 Bank debt 2024: € 22,739 ▼ 23% vs 2023 (€ 29,456) Favourable step	€ 15,804 Bank debt 2025: € 15,804 ▼ 30% vs 2024 (€ 22,739) Favourable step	▼ 30%
Balance sheet total	€ 52,352 Balance sheet total 2022: € 52,352 First fiscal year in the series	€ 92,258 Balance sheet total 2023: € 92,258 ▲ 76% vs 2022 (€ 52,352) Unchanged	€ 101,078 Balance sheet total 2024: € 101,078 ▲ 10% vs 2023 (€ 92,258) Unchanged	€ 93,620 Balance sheet total 2025: € 93,620 ▼ 7% vs 2024 (€ 101,078) Unchanged	▼ 7%

Key figures of S.G. Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to S.G. Pharma?

What happened at S.G. Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 1, 2026 New annual accounts for financial year 2025: profit of € 14,601 (▼ 8% vs 2024). Source: NBB ↗
Jan 25, 2021 New establishment in Aalst. KBO
2021 Santina Gorsen became a director. NBB
Jan 25, 2021 Start of the company according to the CBE. KBO

In short

From € 23,310 profit in 2022 to € 14,601 profit in 2025.

Paid € 34,949 in corporate taxes since 2022.

Best year ever: 2022, with € 23,310 profit.

Paid out € 16,064 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at S.G. Pharma? We notify you, reason included.

Follow S.G. Pharma

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Santina Gorsen

S.G. Pharma

Behind S.G. Pharma is Santina Gorsen.

See the full network in the app

Directors

According to the 2025 annual accounts

Santina Gorsen

Director

since 2021

Establishments

Establishment units

Physical locations of this company

Registered office

Moorselbaan 345

9300 Aalst

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

Light Your Sound

€ 33,012 gross margin · 2025

Sounds like Ken

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0762.459.887
VAT number: BE 0762.459.887
Registered office: Moorselbaan 345, 9300 Aalst
Names & denominations: S.G. Pharma
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 25 January 2021
Peppol: Active · Active since 11 Sept 2026
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗